Axiom Investors LLC DE Sells 27,599 Shares of Merit Medical Systems, Inc. (NASDAQ:MMSI)

Axiom Investors LLC DE decreased its position in shares of Merit Medical Systems, Inc. (NASDAQ:MMSI) by 12.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 186,018 shares of the medical instruments supplier’s stock after selling 27,599 shares during the period. Axiom Investors LLC DE owned approximately 0.32% of Merit Medical Systems worth $17,992,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. NewSquare Capital LLC bought a new position in Merit Medical Systems during the fourth quarter worth about $32,000. Kohmann Bosshard Financial Services LLC bought a new position in shares of Merit Medical Systems during the fourth quarter worth approximately $52,000. Smartleaf Asset Management LLC raised its position in shares of Merit Medical Systems by 237.7% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,388 shares of the medical instruments supplier’s stock valued at $134,000 after buying an additional 977 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of Merit Medical Systems by 14.7% in the fourth quarter. GAMMA Investing LLC now owns 1,494 shares of the medical instruments supplier’s stock valued at $144,000 after buying an additional 191 shares during the period. Finally, TD Private Client Wealth LLC grew its position in Merit Medical Systems by 13.9% during the third quarter. TD Private Client Wealth LLC now owns 1,732 shares of the medical instruments supplier’s stock worth $171,000 after buying an additional 211 shares in the last quarter. Institutional investors and hedge funds own 99.66% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on MMSI. Barrington Research cut their target price on Merit Medical Systems from $115.00 to $111.00 and set an “outperform” rating for the company in a research report on Wednesday, February 26th. Wells Fargo & Company cut their price objective on shares of Merit Medical Systems from $120.00 to $117.00 and set an “overweight” rating for the company in a research report on Wednesday, February 26th. Raymond James raised their target price on shares of Merit Medical Systems from $105.00 to $110.00 and gave the company an “outperform” rating in a report on Tuesday, December 31st. JPMorgan Chase & Co. started coverage on shares of Merit Medical Systems in a report on Friday. They set an “overweight” rating and a $120.00 price target for the company. Finally, Piper Sandler reissued an “overweight” rating and issued a $116.00 price objective (up from $114.00) on shares of Merit Medical Systems in a research note on Wednesday, January 29th. Two research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $111.70.

Merit Medical Systems Trading Up 0.6 %

NASDAQ MMSI opened at $103.94 on Monday. The company has a market cap of $6.12 billion, a price-to-earnings ratio of 50.95, a price-to-earnings-growth ratio of 2.34 and a beta of 0.91. Merit Medical Systems, Inc. has a twelve month low of $70.70 and a twelve month high of $111.45. The company has a quick ratio of 3.82, a current ratio of 5.36 and a debt-to-equity ratio of 0.57. The business’s fifty day moving average is $104.30 and its 200 day moving average is $101.06.

Insider Transactions at Merit Medical Systems

In other news, CFO Raul Jr. Parra sold 5,361 shares of Merit Medical Systems stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $103.58, for a total transaction of $555,292.38. Following the transaction, the chief financial officer now owns 24,201 shares in the company, valued at approximately $2,506,739.58. The trade was a 18.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Stephen C. Evans sold 5,000 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $105.31, for a total value of $526,550.00. Following the completion of the sale, the director now owns 4,657 shares of the company’s stock, valued at $490,428.67. The trade was a 51.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 109,132 shares of company stock worth $11,139,521. Insiders own 3.70% of the company’s stock.

About Merit Medical Systems

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.